We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Traditional Chinese Medicine Xihuang Wan Inhibited Lewis Lung Carcinoma in a Syngeneic Model, Equivalent to Cytotoxic Chemotherapy, by Altering Multiple Signaling Pathways.
- Authors
ZHIYING ZHANG; JIANFENG WANG; HUA DUAN; DIANNA LIU; XIANGNAN ZHOU; XIMING LIN; HAOYUE PANG; MANQIANG SUN; TIAN ZHOU; HOFFMAN, ROBERT M.; KAIWEN HU
- Abstract
Background/Aim: Xihuang Wan (XHW), a traditional Chinese medicine (TCM), has been used in China for a variety of cancers including lung cancer. The present study evaluated the efficacy of XHW on a Lewis lung mouse model and explored the potential mechanism via transcriptomics. Materials and Methods: The mice were randomized into 6 groups: 1) untreated control (n=10); 2) low-dose XHW; 3) medium-dose XHW; 4) high-dose XHW; 5) cisplatin; and 6) untreated blank (n=4). Lewis lung carcinoma (LLC) cells were injected subcutaneously except for the 4 mice in the blank group. The body weight and tumor length and width were measured every 3 days. RNAsequencing was performed on tumors in the high-dose XHW group and the control group. Results: XHW inhibited the growth of LLC in a syngeneic mouse model, without toxicity, with equivalent efficacy to cisplatin. RNA-sequencing demonstrated that many signaling pathways were involved in XHW-mediated inhibition of LLC, including tumor necrosis factor, estrogen, cyclic guanosine 3', 5'-monophosphate-protein kinase G, apelin and the peroxisome proliferator-activated receptor signaling pathways. Conclusion: XHW inhibited LLC carcinoma through different pathways and shows clinical promise for patients who cannot tolerate platinum-based drugs.
- Subjects
CHINESE medicine; LUNG cancer; CANCER chemotherapy; CELLULAR signal transduction; LABORATORY mice
- Publication
In Vivo, 2021, Vol 35, Issue 4, p2005
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12469